Creative Touch Permanent Makeup and Aesthetics

Oestrogen is a systemic steroid hormone and a primary regulator of skin homeostasis across all compartments. Operating through nuclear receptors (ERα and ERβ) in both fibroblasts and keratinocytes, it sustains collagen synthesis, inhibits Matrix Metalloproteinase (MMP) degradation, and maintains the hyaluronic acid ground substance. Critically, oestrogen withdrawal at menopause triggers a multi-system failure: a 30% loss of dermal collagen in five years, epidermal thinning, and a specific impairment of ceramide hydrolysis. In the clinic, post-menopausal skin is defined by a “maturation deficit” where the primary issue is not necessarily a lack of production signals, but a failure in protein maturation and lipid processing that requires direct substrate supply and enzymatic support.

Oestrogen is not a skin hormone in the narrow sense, it is a systemic steroid hormone whose skin effects are extensive and well-characterised because skin is a highly oestrogen-sensitive organ. Dermal fibroblasts express both oestrogen receptor alpha (ERα) and oestrogen receptor beta (ERβ), with ERβ expressed at higher levels in female skin fibroblasts. ^[2] Epidermal keratinocytes also express oestrogen receptors, giving oestrogen direct regulatory access to both the dermal structural compartment and the epidermal barrier production chain simultaneously. The skin effects of oestrogen are not mediated through a single downstream pathway; they operate through several independent mechanisms in parallel, which is why the decline at menopause produces changes across multiple aspects of skin biology at once rather than through one primary route.

The Oestrogen Receptor (ER) Map

Oestrogen and Collagen

The collagen effect is the most consistently cited and quantitatively best-characterised oestrogen–skin relationship. Type I and III dermal collagen decreases by up to 30% in the first five years after menopause, with an ongoing loss of approximately 2% per year thereafter; skin thickness decreases by approximately 1.1% per year. ^[6] The mechanism operates at the level of fibroblast ERβ – oestradiol upregulates collagen synthesis in fibroblasts through ERβ-mediated pathways, and ERβ-deficient fibroblasts lose responsiveness to oestradiol’s stimulatory collagen effects despite higher baseline collagen production. ^[3] Oestrogen also suppresses MMP-1 expression in fibroblasts, reducing collagen degradation alongside its synthesis-stimulating role – meaning that oestrogen withdrawal affects both sides of the collagen balance simultaneously. ^[5]

The clinical precision that matters here – and that the Collagen entity establishes in detail – is that menopausal fibroblasts increase procollagen gene transcription as a compensatory response, yet net collagen still declines because of simultaneous MMP upregulation and impaired procollagen maturation. Oestrogen withdrawal does not simply turn off collagen production. It shifts the balance of an already-complex multi-step process in ways that require treatment strategies addressing multiple points in the pathway rather than transcription alone.

Oestrogen and Ceramide Production

Research published in 2022 established a specific and previously underappreciated oestrogen–ceramide relationship at the stratum corneum level. Analysis of stratum corneum lipids from pre-menopausal, post-menopausal, and HRT-treated women found significantly reduced total ceramide levels post-menopause, with HRT normalising ceramide profiles toward pre-menopausal values. Critically, post-menopausal women showed elevated sphingomyelin levels – a ceramide precursor – suggesting the deficit sits at the hydrolysis step rather than upstream synthesis. ^[10] Oestradiol treatment of primary human keratinocytes directly increased production of CER[NS] and CER[NDS] ceramide subtypes, confirming that oestrogen exerts a direct effect on keratinocyte ceramide metabolism rather than an indirect one mediated through other hormonal pathways.

This is a distinct mechanism from the inflammatory suppression of ceramide synthesis described in the Ceramides entity. Where IL-4 and IL-13 suppress the synthesis enzymes (SPT, ELOVL elongases), oestrogen withdrawal appears to impair the hydrolysis of ceramide precursors – a different point of failure in the same overall production chain. The clinical implication is that post-menopausal ceramide deficiency may not respond to the same interventions as inflammation-driven ceramide deficiency, and that restoring the inflammatory environment alone is insufficient when the hormonal substrate for ceramide hydrolysis has also been lost.

The Post-Menopausal “Maturation Gap”

Oestrogen and Hyaluronic Acid

Oestrogen stimulates hyaluronic acid synthesis in skin through a pathway that involves EGF signalling: oestrogen induces EGF expression in keratinocytes, which then stimulates hyaluronic acid synthase 3 (HAS3) and versican expression in dermal fibroblasts. ^[7] HAS3 knockdown in this model inhibited fibroblast proliferation, indicating that the HA matrix component is not merely a hydration reservoir but part of the proliferative signalling environment of the dermis – consistent with the mechanosensitivity framework established in the Fibroblast entity. Earlier animal research confirmed that topical oestradiol increases hyaluronic acid synthase activity in skin in a receptor-mediated, anti-oestrogen-blockable manner. ^[9] The post-menopausal decline in dermal HA therefore reflects not simply reduced production but the loss of the hormonal signal that was sustaining HAS3 expression and the ground substance environment that fibroblasts depend on for mechanosensory input.

Oestrogen and Wound Healing

Oestrogen is a significant regulator of cutaneous wound repair. Oestrogen-deficient skin shows excessive early-phase leukocyte recruitment, reduced matrix deposition at wound sites, and impaired re-epithelialisation. ^[1] The mechanism involves oestrogen’s suppression of macrophage migration inhibitory factor (MIF), a proinflammatory cytokine whose elevated activity in oestrogen-deficient wounds prolongs the inflammatory phase and impairs the transition to repair. ERα and ERβ mediate distinct aspects of the healing response – ERα agonism increases fibroblast migration and keratinocyte proliferation through TGF-β1-dependent pathways, whilst ERβ agonism accelerates re-epithelialisation through a TGF-β1-independent route. ^[4]

The clinical relevance extends beyond injury response to treatment recovery. Professional treatments at Creative Touch – microneedling, RF microneedling, thulium laser, iPRF – all initiate controlled wound-healing cascades. In post-menopausal clients, the same oestrogen-deficiency mechanisms that impair natural wound healing apply to treatment-induced healing responses, potentially extending recovery timelines and attenuating the fibroblast activation that these treatments depend on for their collagen synthesis outcomes.

Oestrogen and Epidermal Thickness

Oestrogen directly influences keratinocyte proliferation through epidermal oestrogen receptors. In oestrogen-deficient women, skin thickness reduces by approximately 1.13% per year; topical oestrogen administration restores keratinocyte proliferation and increases epidermal thickness within two weeks – a direct receptor-mediated effect. ^[8] This epidermal thinning is independent of and additive to the dermal collagen loss. It is a separate oestrogen-withdrawal effect operating in the epidermal compartment whilst collagen loss operates in the dermal compartment. The convergence of thinner epidermis, reduced ceramides, depleted dermal collagen, reduced HA, and impaired wound healing in post-menopausal skin reflects the simultaneous withdrawal of oestrogen’s regulatory effects across multiple skin compartments, not a single cascade from one primary change.